financing

The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.

The firm said the financing enables it to progress with the development of an algorithm that would help detect the most common cancers.

The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.

Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.

Enzyre is developing a near-patient platform called Enzypad to measure biomarkers in body fluids. The first application will be the monitoring of hemophilia.

The proceeds from the round will allow the firm to begin selling its in vitro diagnostic blood test for patients with chronic kidney disease.

The company plans to use the proceeds of the round to fund ongoing development and commercialization of its point-of-care diagnostic platform.

The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types. 

ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.

The company will use proceeds from the offering to pay off debt related to other notes and to partially fund a redemption of other notes.